Literature DB >> 17669451

Acute viscerotropic disease following vaccination against yellow fever.

Edward B Hayes1.   

Abstract

Acute viscerotropic disease following yellow fever vaccination (YEL-AVD) is a rare but serious complication of vaccination with 17D yellow fever vaccine. This paper reviews the existing literature regarding YEL-AVD and discusses possible etiologic mechanisms. A greater understanding of this condition is essential to assuring safe and effective prevention of yellow fever and vaccination against other arboviral diseases for which 17D-based vaccines are being developed.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17669451     DOI： 10.1016/j.trstmh.2007.06.013

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN： 0035-9203            Impact factor:   2.184


  22 in total

1.  Mapping the risk of yellow Fever infection.

Authors:  David R Hill
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

Review 2.  Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004-2009.

Authors:  S Elizabeth Williams; Nicola P Klein; Neal Halsey; Cornelia L Dekker; Roger P Baxter; Colin D Marchant; Philip S LaRussa; Robert C Sparks; Jerome I Tokars; Barbara A Pahud; Laurie Aukes; Kathleen Jakob; Silvia Coronel; Howard Choi; Barbara A Slade; Kathryn M Edwards
Journal:  Vaccine       Date:  2011-07-27       Impact factor: 3.641

3.  Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model.

Authors:  Justin G Julander; Dennis W Trent; Thomas P Monath
Journal:  Vaccine       Date:  2011-06-28       Impact factor: 3.641

4.  Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States.

Authors:  Thomas P Monath
Journal:  Am J Trop Med Hyg       Date:  2010-05       Impact factor: 2.345

5.  Incubation periods of Yellow fever virus.

Authors:  Michael A Johansson; Neysarí Arana-Vizcarrondo; Brad J Biggerstaff; J Erin Staples
Journal:  Am J Trop Med Hyg       Date:  2010-07       Impact factor: 2.345

6.  STATEMENT FOR TRAVELLERS AND YELLOW FEVER: An Advisory Committee Statement (ACS) Committee to Advise on Tropical Medicine and Travel (CATMAT).

Authors:  This Statement Was Prepared By P Charlebois
Journal:  Can Commun Dis Rep       Date:  2013-03-05

7.  Statement for Travellers and Yellow Fever: Committee to Advise on Tropical Medicine and Travel.

Authors:  P Charlebois
Journal:  Can Commun Dis Rep       Date:  2010-10-02

8.  Construction and characterization of a single-cycle chimeric flavivirus vaccine candidate that protects mice against lethal challenge with dengue virus type 2.

Authors:  Ryosuke Suzuki; Evandro R Winkelmann; Peter W Mason
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

9.  Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers.

Authors:  Ricardo Carrion; Peter Bredenbeek; Xiaohong Jiang; Irina Tretyakova; Peter Pushko; Igor S Lukashevich
Journal:  J Vaccines Vaccin       Date:  2012-11-20

10.  A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: comparative viremia and immunogenicity.

Authors:  Srilatha Edupuganti; Rachel B Eidex; Harry Keyserling; Rama S Akondy; Robert Lanciotti; Walter Orenstein; Carlos del Rio; Yi Pan; Troy Querec; Harvey Lipman; Alan Barrett; Rafi Ahmed; Dirk Teuwen; Martin Cetron; Mark J Mulligan
Journal:  Am J Trop Med Hyg       Date:  2012-12-03       Impact factor: 2.345
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.